244 related articles for article (PubMed ID: 34666780)
1. Metabolic reprogramming in cervical cancer and metabolomics perspectives.
Li B; Sui L
Nutr Metab (Lond); 2021 Oct; 18(1):93. PubMed ID: 34666780
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics study reveals the potential evidence of metabolic reprogramming towards the Warburg effect in precancerous lesions.
Chen X; Yi C; Yang MJ; Sun X; Liu X; Ma H; Li Y; Li H; Wang C; He Y; Chen G; Chen S; Yu L; Yu D
J Cancer; 2021; 12(5):1563-1574. PubMed ID: 33532002
[No Abstract] [Full Text] [Related]
3. Effect of HPV Oncoprotein on Carbohydrate and Lipid Metabolism in Tumor Cells.
Chen B; Wang Y; Wu Y; Xu T
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38284713
[TBL] [Abstract][Full Text] [Related]
4. Gastric cancer: Metabolic and metabolomics perspectives (Review).
Xiao S; Zhou L
Int J Oncol; 2017 Jul; 51(1):5-17. PubMed ID: 28535006
[TBL] [Abstract][Full Text] [Related]
5. When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective.
Zhang Z; Bao C; Jiang L; Wang S; Wang K; Lu C; Fang H
Front Oncol; 2022; 12():1054233. PubMed ID: 36686803
[TBL] [Abstract][Full Text] [Related]
6. Combined Transcriptome and Proteome Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16) Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis.
Yang R; Klimentová J; Göckel-Krzikalla E; Ly R; Gmelin N; Hotz-Wagenblatt A; Řehulková H; Stulík J; Rösl F; Niebler M
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918060
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Reprogramming in Cancer: Role of HPV 16 Variants.
Arizmendi-Izazaga A; Navarro-Tito N; Jiménez-Wences H; Mendoza-Catalán MA; Martínez-Carrillo DN; Zacapala-Gómez AE; Olea-Flores M; Dircio-Maldonado R; Torres-Rojas FI; Soto-Flores DG; Illades-Aguiar B; Ortiz-Ortiz J
Pathogens; 2021 Mar; 10(3):. PubMed ID: 33809480
[TBL] [Abstract][Full Text] [Related]
8. LC/MS-Based Polar Metabolite Profiling Identified Unique Biomarker Signatures for Cervical Cancer and Cervical Intraepithelial Neoplasia Using Global and Targeted Metabolomics.
Khan I; Nam M; Kwon M; Seo SS; Jung S; Han JS; Hwang GS; Kim MK
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30974861
[TBL] [Abstract][Full Text] [Related]
9. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
10. Targeted cancer therapeutics: biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors.
Dang NH; Singla AK; Mackay EM; Jirik FR; Weljie AM
Curr Pharm Des; 2014; 20(15):2637-47. PubMed ID: 23859615
[TBL] [Abstract][Full Text] [Related]
11. Recent Metabolomics Analysis in Tumor Metabolism Reprogramming.
Han J; Li Q; Chen Y; Yang Y
Front Mol Biosci; 2021; 8():763902. PubMed ID: 34901157
[TBL] [Abstract][Full Text] [Related]
12. The metabolomic signature of hematologic malignancies.
Allegra A; Innao V; Gerace D; Bianco O; Musolino C
Leuk Res; 2016 Oct; 49():22-35. PubMed ID: 27526405
[TBL] [Abstract][Full Text] [Related]
13. HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer.
Zhang R; Su J; Xue SL; Yang H; Ju LL; Ji Y; Wu KH; Zhang YW; Zhang YX; Hu JF; Yu MM
Am J Cancer Res; 2016; 6(2):312-20. PubMed ID: 27186405
[TBL] [Abstract][Full Text] [Related]
14. Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis.
Feng D; Yan K; Zhou Y; Liang H; Liang J; Zhao W; Dong Z; Ling B
Oncotarget; 2016 Oct; 7(40):64575-64588. PubMed ID: 27602489
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms in progression of HPV-associated cervical carcinogenesis.
Gupta SM; Mania-Pramanik J
J Biomed Sci; 2019 Apr; 26(1):28. PubMed ID: 31014351
[TBL] [Abstract][Full Text] [Related]
16. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
17. Discriminating high-risk cervical Human Papilloma Virus infections with urinary biomarkers via non-targeted GC-MS-based metabolomics.
Godoy-Vitorino F; Ortiz-Morales G; Romaguera J; Sanchez MM; Martinez-Ferrer M; Chorna N
PLoS One; 2018; 13(12):e0209936. PubMed ID: 30592768
[TBL] [Abstract][Full Text] [Related]
18. Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.
Martin CM; Kehoe L; Spillane CO; O'Leary JJ
Mol Diagn Ther; 2007; 11(5):277-90. PubMed ID: 17963416
[TBL] [Abstract][Full Text] [Related]
19. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis.
Chen L; Qiu X; Zhang N; Wang Y; Wang M; Li D; Wang L; Du Y
Biosci Trends; 2017 Sep; 11(4):383-388. PubMed ID: 28717061
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
